U.S. pharma giant copyright scrapped two experimental weight loss pills final year—a when-day by day tablet, lotiglipron, due to elevated liver enzymes along with a 2 times-each day capsule, danuglipron, due to robust Unwanted side effects—but CEO Albert Bourla has mentioned the company is determined to “Participate in and acquire” during t